Ireland
--:--IST
Starting soon Not applicable

Comparison of TAP Block and Umbilical Paramedian Linea Semilunaris Block in Pediatric Laparoscopic Surgery

NCT07801794 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-08-25
Last updated
2026-09-03

Condition(s) studied

Postoperative PainOpioid Consumption

Investigational drug(s) / intervention(s)

Ultrasound-Guided Transversus Abdominis Plane BlockUltrasound-Guided Linea Semilunaris Block

Ultrasound-Guided Transversus Abdominis Plane Block: Following induction of general anesthesia and before the start of surgery, an ultrasound-guided transversus abdominis plane (TAP) block will be performed. After identification of the target fascial plane and confirmation by hydrodissection, 0.2% bupivacaine will be administered at a volume of 0.5 mL/kg. The total bupivacaine dose will be limited to 2 mg/kg.

Ultrasound-Guided Linea Semilunaris Block: Following induction of general anesthesia and before the start of surgery, an ultrasound-guided umbilical paramedian linea semilunaris block will be performed. The linea semilunaris will be identified under ultrasound guidance, and the appropriate fascial plane will be confirmed by hydrodissection. Subsequently, 0.2% bupivacaine will be administered at a volume of 0.5 mL/kg. The total bupivacaine dose will be limited to 2 mg/kg.

Study summary

The aim of this prospective randomized controlled trial is to compare the postoperative analgesic efficacy of ultrasound-guided transversus abdominis plane (TAP) block and umbilical paramedian linea semilunaris block in pediatric patients undergoing elective laparoscopic abdominal surgery.

A total of 56 pediatric patients will be randomly assigned in a 1:1 ratio to receive either a TAP block or a linea semilunaris block after induction of general anesthesia and before the start of surgery. Both blocks will be performed under ultrasound guidance using 0.2% bupivacaine at a volume of 0.5 mL/kg, with the total dose limited to 2 mg/kg.

The primary outcome will be total opioid consumption during the first 24 hours after surgery. Secondary outcomes will include postoperative pain scores, time to first analgesic requirement, additional analgesic requirements, postoperative nausea and vomiting, and block-related complications.

Eligibility

Sex
ALL
Min age
1 Year
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Patients scheduled for elective pediatric laparoscopic abdominal surgery * Age within the specified eligibility range * American Society of Anesthesiologists (ASA) physical status I or II * Written informed consent provided by a parent or legal guardian * Adequate ultrasound visualization for the planned regional block * No known allergy to bupivacaine or ultrasound gel * No coagulopathy * No infection at the block injection site * No previous surgery at the block injection site * No anticipated requirement for postoperative intensive care unit admission Exclusion Criteria: * Refusal of the parent or legal guardian to participate * Emergency surgery * Inadequate ultrasound visualization * Coagulopathy * Infection or previous surgery at the block injection site * Known allergy to bupivacaine or ultrasound gel * Conversion from laparoscopic to open surgery * Requirement for postoperative intensive care unit admission * ASA physical status III or higher

Primary outcome measure(s)

  • Total Postoperative Opioid Consumption During the First 24 Hours — First 24 hours after surgery
    Total opioid consumption administered for postoperative analgesia will be recorded during the first 24 hours after surgery.

Trial sites (1)

FacilityCityRegionStatus
Dicle University Faculty of Medicine Hospital Diyarbakır Diyarbakır
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07801794 on ClinicalTrials.gov ↗ ← All trials in Turkey